What is the role of kidney function in the use of SGLT2 inhibitors?

• A. Efficacy and safety depend on renal function; many agents require adequate eGFR and dosing adjustments
• B. They work equally well at all eGFR levels
• C. They do not depend on kidney function
• D. They are only approved for liver-impaired patients

Answer: (A)

The key idea is that kidney function directly shapes both how well SGLT2 inhibitors work and how safe they are to use. These drugs lower glucose by blocking SGLT2 in the proximal tubule, which causes filtered glucose to be excreted in urine. That whole effect depends on how much glucose the kidneys are filtering, which is set by the glomerular filtration rate (eGFR). When eGFR is sufficiently high, enough glucose is filtered, so inhibiting its reabsorption yields meaningful glucose lowering. As eGFR declines, less glucose is filtered, so the drug’s glucosuria effect—and thus its blood glucose–lowering efficacy—wanes. Because kidney function also influences drug exposure and the risk of adverse events, many agents have eGFR thresholds for initiation or continuation and may require dosing adjustments at lower levels.

So, the statement that efficacy and safety depend on renal function and that dosing adjustments are often needed based on eGFR best captures how SGLT2 inhibitors are used in practice.